Version 1
: Received: 18 December 2023 / Approved: 20 December 2023 / Online: 20 December 2023 (09:09:38 CET)
How to cite:
Barnett, B.P.; Gargiulo, S.; Randolph, S.; Lundquist, K.; Schafer, B. Multimodal Imaging of the Bimatoprost Sustained Release Implant (Durysta) after Intracameral and Middle Segment Delivery. Preprints2023, 2023121519. https://doi.org/10.20944/preprints202312.1519.v1
Barnett, B.P.; Gargiulo, S.; Randolph, S.; Lundquist, K.; Schafer, B. Multimodal Imaging of the Bimatoprost Sustained Release Implant (Durysta) after Intracameral and Middle Segment Delivery. Preprints 2023, 2023121519. https://doi.org/10.20944/preprints202312.1519.v1
Barnett, B.P.; Gargiulo, S.; Randolph, S.; Lundquist, K.; Schafer, B. Multimodal Imaging of the Bimatoprost Sustained Release Implant (Durysta) after Intracameral and Middle Segment Delivery. Preprints2023, 2023121519. https://doi.org/10.20944/preprints202312.1519.v1
APA Style
Barnett, B.P., Gargiulo, S., Randolph, S., Lundquist, K., & Schafer, B. (2023). Multimodal Imaging of the Bimatoprost Sustained Release Implant (Durysta) after Intracameral and Middle Segment Delivery. Preprints. https://doi.org/10.20944/preprints202312.1519.v1
Chicago/Turabian Style
Barnett, B.P., Karen Lundquist and Barry Schafer. 2023 "Multimodal Imaging of the Bimatoprost Sustained Release Implant (Durysta) after Intracameral and Middle Segment Delivery" Preprints. https://doi.org/10.20944/preprints202312.1519.v1
Abstract
Currently the bimatoprost implant (DURYSTA) is approved for a single administration secondary to concern for progressive corneal endothelial cell (CEC) loss with intracameral administration. In order to better understand the cause of CEC loss and other adverse events (AEs) with intracameral administration, multimodal imaging of the implant utilizing optical coherence topography (OCT), robotic ultrasound and bio microscopy video recording was utilized. Inherently the anterior chamber is a non-confined space. In certain examples the implant assumed a round and spotted structure as it picked up iris pigment as it migrated around the anterior chamber. Accordingly, we explored delivery of the implant in the middle segment behind the iris and in front of the pseudophakic lens. We then evaluated the suitability of various imaging modalities to assess the implant in this location. For middle segment administration, the ArcScan Insight 100 robotic ultrasound provided resolution and repeatability sufficient to monitor the implant behind the iris. This preliminary study hypothesizes that DURYSTA migration in the anterior chamber is the main source of AEs. Through use of a confined location, the middle segment, the implant is unlikely to migrate and cause CEC loss while also delivering drug closer to its site of action, the ciliary body. Further efforts are underway to understand the suitability of the middle segment for serial DURYSTA administration to maximize intraocular pressure lowering while minimizing AEs.
Keywords
Durysta, Bimatoprost; Ciliary Sulcus, Middle Space Operations; MiSO; Middle Space Therapeutics; MiST; ArcScan; Ultrasound; Depot; Drug Delivery; Posterior Chamber; Sulcus
Subject
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
